Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database

Renfro, Lindsay A., Loupakis, Fotios, Adams, Richard A. ORCID: https://orcid.org/0000-0003-3915-7243, Seymour, Matthew T., Heinemann, Volker, Schmoll, Hans-Joachim, Douillard, Jean-Yves, Hurwitz, Herbert, Fuchs, Charles S., Diaz-Rubio, Eduardo, Porschen, Rainer, Tournigand, Christophe, Chibaudel, Benoist, Falcone, Alfredo, Tebbutt, Niall C., Punt, Cornelis J.A., Hecht, J. Randolph, Bokemeyer, Carsten, Van Cutsem, Eric, Goldberg, Richard M., Saltz, Leonard B., de Gramont, Aimery, Sargent, Daniel J. and Lenz, Heinz-Josef 2016. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. Journal of Clinical Oncology 34 (2) , pp. 144-150. 10.1200/JCO.2015.61.6441

Full text not available from this repository.

Abstract

Purpose In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear. Patients and Methods Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted). Results BMI was prognostic for overall survival (P < .001) and progression-free survival (P < .001), with an L-shaped pattern. That is, risk of progression and/or death was greatest for low BMI; risk decreased as BMI increased to approximately 28 kg/m2, and then it plateaued. Relative to obese patients, patients with a BMI of 18.5 kg/m2 had a 27% increased risk of having a PFS event (95% CI, 20% to 34%) and a 50% increased risk of death (95% CI, 43% to 56%). Low BMI was associated with poorer survival for men than women (interaction P < .001). BMI was not predictive of treatment effect. Conclusion Low BMI is associated with an increased risk of progression and death among the patients enrolled on the mCRC trials, with no increased risk for elevated BMI, in contrast to the adjuvant setting. Possible explanations include negative effects related to cancer cachexia in patients with low BMI, increased drug delivery or selection bias in patients with high BMI, and potential for an interaction between BMI and molecular signaling pathways.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Centre for Trials Research (CNTRR) Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	American Society of Clinical Oncology
ISSN:	0732-183X
Last Modified:	01 Nov 2022 11:14
URI:	https://orca.cardiff.ac.uk/id/eprint/94299

Citation Data

Cited 87 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item